Introduction Antibody-drug conjugates (ADC) therapy has rapidly developed over the past few decades, with 14 products approved globally and over 140 ADCs currently in clinical trials. By 2030, the ADC market is expected to exceed $15 billion. The basic principle of ADCs is that by combining the specificity of monoclonal antibodies with the cytotoxicity of … Read more
LC-MS/MS ADC Drug Biological Analysis A Dual Advantage in Speed and Cost 0 1 Definition of Antibody-Drug Conjugates (ADC) Antibody-drug conjugates (ADC) consist of an antibody, a cytotoxic drug, and a linker (as shown in Figure 1[1]), and are considered an innovative therapeutic approach targeting various types of tumors and cancers. They can enhance the … Read more
▲May 2022, Improved New Drug Trends and Technology Conference·Limited TimeFree Registration Ongoing Note:This article does not constitute any investment opinions or advice, subject to official/company announcements;This article is only for the introduction of medical health-related drugs, not a recommendation for treatment plans (if involved), and does not represent the platform’s position.Any article reproduction requires authorization. … Read more
▉ Introduction Antibody-drug conjugates (ADCs) are currently developing rapidly, utilizing antibodies to selectively deliver cytotoxic drugs to tumor sites. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved 10 ADCs, including Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Polivy®, Padcev®, Enhertu®, Trodvy®, Blenrep®, and Zynlonta™ for use as monotherapy or in combination for the … Read more
–01– Introduction Antibody-drug conjugates (ADC) are known as “magic bullets” that precisely target tumor cells through antibodies, delivering cytotoxic drugs while combining the precision of targeted therapy with the potent killing power of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field … Read more
Chemotherapy based on cytotoxic drugs has always been a primary method for treating malignant tumors. However, due to the lack of targeted killing of tumor cells, there are significant toxic reactions, and as the number of chemotherapy cycles increases, tumor resistance also enhances. The challenge of how to target tumor cells to deliver cytotoxic drugs … Read more
In 2019, a CT imaging comparison from Gustave Roussy Hospital in Paris, France, caused a stir in the oncology community: a late-stage non-small cell lung cancer patient, who had failed both chemotherapy and immunotherapy, showed significant reduction in systemic metastatic lesions just two months after being enrolled in the clinical trial of Trastuzumab Deruxtecan (T-DXd), … Read more
Breast cancer, regarded as the “killer of beauty,” is a malignant tumor that severely threatens women’s health, with an increasing incidence year by year. Antibody-drug conjugates (ADC), as a new type of therapeutic drug, have become a hot research topic in the field of breast cancer due to their advantages of “high efficacy and low … Read more
Introduction: Antibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule cytotoxic drugs, combining high specificity and high cytotoxicity advantages. However, their structural diversity and complexity, along with the low content of released small molecule toxins in the circulatory system, pose significant challenges for pharmacokinetic studies. This article will discuss the mechanisms, design, safety features, … Read more
Antibody-Drug Conjugates (ADCs) are one of the fastest-developing treatments in the field of oncology, with 15 ADCs already approved and over 210 currently undergoing clinical trials. In recent years, the development of ADC drugs has entered a flourishing phase, especially demonstrating significant efficacy and good safety profiles against targets such as HER2, EGFR, Trop2, CLDN18.2, … Read more